| Jaswinder Singh, MD | |
|
2316 E Meyer Blvd, 1 Cancer West, Kansas City, MO 64132-1136 | |
| (816) 276-4700 | |
| (816) 276-3810 |
| Full Name | Jaswinder Singh |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 27 Years |
| Location | 2316 E Meyer Blvd, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093747677 | NPI | - | NPPES |
| 100422980F | Medicaid | KS | |
| 100422980 D | Medicaid | KS | |
| 100422980E | Medicaid | KS | |
| 1093747677 | Medicaid | MO | |
| 205876402 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 2002013739 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Golden Valley Memorial Hospital | Clinton, MO | Hospital |
| Research Medical Center | Kansas city, MO | Hospital |
| Cass Regional Medical Center | Harrisonville, MO | Hospital |
| Belton Regional Medical Center | Belton, MO | Hospital |
| Bates County Memorial Hospital | Butler, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Oncology Associates Llc | 3779635172 | 57 |
| Midwest Oncology Associates Llc | 3779635172 | 57 |
| Kansas City Urology Care Pa | 9032006853 | 61 |
News Archive
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.
A new study has found kids who learn how to kick, catch and throw are more likely to grow into active and fit teens.
Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
The Autism Science Foundation, a not-for-profit organization dedicated to supporting and funding autism research, today announced the launch of the Autism Sisters Project, a new initiative that will give unaffected sisters of individuals with autism the opportunity to take an active role in accelerating research into the "Female Protective Effect."
› Verified 2 days ago
| Entity Name | Excelsior Springs City Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285733923 PECOS PAC ID: 7315847209 Enrollment ID: O20040108000958 |
News Archive
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.
A new study has found kids who learn how to kick, catch and throw are more likely to grow into active and fit teens.
Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
The Autism Science Foundation, a not-for-profit organization dedicated to supporting and funding autism research, today announced the launch of the Autism Sisters Project, a new initiative that will give unaffected sisters of individuals with autism the opportunity to take an active role in accelerating research into the "Female Protective Effect."
› Verified 2 days ago
| Entity Name | Midwest Oncology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699911677 PECOS PAC ID: 3779635172 Enrollment ID: O20090716000071 |
News Archive
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.
A new study has found kids who learn how to kick, catch and throw are more likely to grow into active and fit teens.
Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
The Autism Science Foundation, a not-for-profit organization dedicated to supporting and funding autism research, today announced the launch of the Autism Sisters Project, a new initiative that will give unaffected sisters of individuals with autism the opportunity to take an active role in accelerating research into the "Female Protective Effect."
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jaswinder Singh, MD 1010 Carondelet Dr, Ste 121, Kansas City, MO 64114-4859 Ph: (816) 605-9756 | Jaswinder Singh, MD 2316 E Meyer Blvd, 1 Cancer West, Kansas City, MO 64132-1136 Ph: (816) 276-4700 |
News Archive
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.
A new study has found kids who learn how to kick, catch and throw are more likely to grow into active and fit teens.
Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
The Autism Science Foundation, a not-for-profit organization dedicated to supporting and funding autism research, today announced the launch of the Autism Sisters Project, a new initiative that will give unaffected sisters of individuals with autism the opportunity to take an active role in accelerating research into the "Female Protective Effect."
› Verified 2 days ago
Maria Akram Sheikh, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Dr. Philip Barigbi Augustine, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4150 N Mulberry Dr, Kansas City, MO 64116 Phone: 816-912-4539 Fax: 855-813-6642 | |
Lucas Vocelka, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2340 E Meyer Blvd, Bldg 2, Suite 392, Kansas City, MO 64132 Phone: 816-444-7977 Fax: 630-528-9578 | |
Karla L Houston-gray, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1004 Carondelet Dr Ste 300, Kansas City, MO 64114 Phone: 816-942-4500 Fax: 816-941-4504 | |
Carl D Dirks, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4320 Wornall Rd, Suite 65, Kansas City, MO 64111 Phone: 816-932-6100 Fax: 816-932-9002 | |
Michelle L Dew, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4330 Wornall Rd, Suite 2000, Kansas City, MO 64111 Phone: 816-931-1883 Fax: 816-756-3645 | |
Brenda J Rogers, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3000 |